腾讯看上了减肥药!又投公司又申请专利,意图何在?

GLP1减重宝典
Feb 13

减重药热潮把一批传统医药玩家推上风口,也把互联网巨头卷进了更深水区。腾讯最近的动作很密集:一边在股权投资上连续加码,从临床后期的GLP-1公司,到押注三靶点的新玩家;另一边又在健康管理、检测与数据处理等方向持续申请和布局专利,把体重管理从一个药品生意,推向一套可复制、可运营、可连接支付与服务的长期体系。如果把这些动作串起来看,腾讯要的可能不是单一一款药的涨跌,而是一条更大的链路:从人群触达、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10